In Brief
This article was originally published in The Gold Sheet
Executive Summary
Question-based review, or QbR, could spread from generics to new drugs. And that’s the way the patent crumbles: FDA’s new tablet-scoring guidance.
You may also be interested in...
FDA’s Tablet Scoring Final Guidance Requires Generics To Be Same As Brand
Generic industry concerns that scoring conventions could create barriers to entry did not win out in final tablet scoring guidance; FDA says to contact it if the scoring convention is patent protected.
AbbVie/Allergan Merger Edges Closer To FTC Clearance
AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.
Another Sterilization Plant Closes For Upgrades; FDA Monitoring Situation For Device Shortage
The US agency is engaged with an ethylene oxide (EtO) sterilizer in Illinois that has temporarily closed to determine if there are any potential risks to the medical device supply chain. While the plant shut down about a month ago, regulators have only recently been made aware of the decision, which resulted from a law passed last year by the state legislature.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: